Site Search
Professionals 127 results
Capabilities 36 results
Industry
Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a unique understanding of the industry and perspective to our representations.
Practice Area
Our Patent Litigation Practice is one of the country’s most active and highly regarded. Our seasoned patent litigators bring extensive courtroom experience to every matter we handle. According to Lex Machina, we are among the top three national patent defense firms in the country for number of appearances and cases filed, and we also were the top national defense firm for number of patent trials in the last five years (2018–2022).
Industry
The medical device industry is currently undergoing monumental change—from supply chain challenges to disruptive technologies and economic fluctuations. To pave the way for a more accessible and innovative healthcare landscape—including advances in wearables, implants, diagnostics, mobility, drug delivery—the evolving and expansive medical device industry faces wide-ranging legal needs. Clients in this sector can tap the remarkable depth and breadth of our sector-focused and skilled attorneys in the U.S. and abroad. Our Healthcare & Life Sciences Industry Group engages clients at all points in the product development life cycle to provide sound advice and practical solutions regardless of the client’s size or the complexity of their need. We help clients navigate today’s complex regulatory landscape, defend products and reputations in the face of high-profile product liability and mass tort claims, protect innovative intellectual property (IP), and leverage cross-border experience to advise on commercial transactions.
Experience 20 results
Experience
|September 23, 2025
Denali Capital Acquisition Corp Closes Business Combination with Semnur Pharmaceuticals
Winston & Strawn LLP represented Denali Capital Acquisition Corp. (OTCQB: DNQAF), a special purpose acquisition company, in the closing of its previously announced business combination with Semnur Pharmaceuticals, Inc., a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies and a majority-owned subsidiary of Scilex Holding Company (Nasdaq: SCLX).
Experience
|April 29, 2024
Winston represented Suntory Global Spirits (f/k/a as Beam Suntory), a world leader in spirits, in its US$1.2B sale of the Courvoisier cognac brand and related assets to Campari Group. Campari Group has assumed full ownership of Courvoisier, including properties and operations in Jarnac, France, intellectual property, maturing inventory, and case finished goods, and will distill, age, and bottle Courvoisier. The transaction will allow Suntory Global Spirits to focus its portfolio on core areas of strength as they accelerate their global growth ambitions.
Experience
|February 12, 2024
A Winston M&A Team represented Empower Clinic Services, LLC, the largest compounding pharmacy operator in the U.S., in the acquisition of a pharmaceutical manufacturing facility, including related equipment and employees, located in New Jersey from Eugia US Manufacturing, LLC, a wholly-owned subsidiary of Eugia, Inc. Winston's Finance Team also represented Empower in obtaining seller financing for this acquisition and related modifications to Empower's existing bank and mezzanine credit facilities.
Insights & News 338 results
Client Alert
|January 13, 2026
|7 Min Read
Key California Labor and Employment Updates for 2026
New California employment statutes include significant changes that will reshape employment agreements, pay equity compliance, notice practices, data governance, and leave administration. Below we summarize the statutes most likely to affect multi-state and California employers beginning January 1, 2026, highlight near-term implementation steps, and flag forward-looking changes coming in 2027 and beyond.
Life at Winston
|October 20, 2025
|1 Min Read
Welcome Winston & Strawn’s U.S. Class of 2025
We are excited to welcome the new members of our U.S. Class of 2025!
Article
|October 7, 2025
|1 Min Read
The High-Stakes Future of Healthcare Consolidation and Regulation
This article was originally published in Financier Worldwide. Any opinions in this article are not those of Winston & Strawn or its clients. The opinions in this article are the authors’ opinions only.
Other Results 26 results
Law Glossary
Generic drugs are typically small, chemically synthesized molecules—that is, they have relatively low molecular weights, frequently less than 1000 daltons and usually between 300 and 700 daltons. Biosimilars, on the other hand, are typically substantially larger in molecular weight than small molecule drugs. For example, a monoclonal antibody—a typical biosimilar drug—generally has a molecular weight in excess of 150,000 daltons. In contrast, aspirin—a typical small molecule drug—has a molecular weight of 180 daltons.
Law Glossary
A biologic—or biologic product—is a medicine made from or by living cells, typically through a series of complex processing steps. The Public Health Service Act defines a “biological product” as “a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein (except any chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine (or another trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings.” (42 U.S.C. § 262(i).)
Law Glossary
How Does an Applicant Establish Biosimilarity?
An applicant typically demonstrates biosimilarity based on non-clinical analyses that focus on the structure and functional differences between the biosimilar and reference product.